NCT07021989 2026-03-17
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
University of California, San Francisco
Phase 2 Not yet recruiting
Clinical Trials
23 trialsNCT03618550 2025-12-02
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06377566 2025-04-20
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03443128 2025-02-13
Vinorelbine for Recurrent ALCL-2017
Children's Cancer Group, China
Phase 2 Completed
NCT00574496 2023-09-28
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03397953 2022-07-26
Vinorelbine for Recurrent ACLC
Children's Cancer Group, China
Phase 2 Completed
NCT00381940 2021-03-24
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003963 2020-08-03
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT02733380 2020-04-01
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Unknown
NCT04021992 2019-08-06
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL
Sun Yat-sen University
Phase 2 Unknown
NCT00388349 2017-06-14
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Stanford University
Phase 2 Completed
NCT00881387 2016-12-15
Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
University of Miami
Phase 2 Withdrawn
NCT00280878 2016-01-15
Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma
Bayside Health
Phase 2 Completed
NCT00163748 2016-01-08
Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma
Bayside Health
Phase 2 Completed
NCT00163761 2016-01-08
Efficacy Study of Outpatient Therapy for Lymphoma
Bayside Health
Phase 2 Completed
NCT00337194 2015-02-23
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00225173 2014-08-27
Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
Stanford University
Phase 2 Terminated
NCT01884441 2014-01-29
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
Istituto Clinico Humanitas
Phase 2 Unknown
NCT00006760 2013-07-26
Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
Children's Oncology Group
Phase 2 Completed
NCT00070304 2013-07-26
Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma
Children's Oncology Group
Phase 2 Completed
NCT00842595 2013-07-24
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
French Innovative Leukemia Organisation
Phase 2 Completed
NCT00636311 2010-09-02
A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma
Istituto Clinico Humanitas
Phase 2 Completed